Predicting treatment success for age-related macular degeneration
Part of Eyes & vision clinical trials.
This trial uses special eye scans to predict how well anti-VEGF treatment will work for patients with a type of age-related macular degeneration called nAMD. It aims to help doctors better understand who will benefit most from this treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have been diagnosed with a specific type of age-related macular degeneration (nAMD) using eye exams like OCT, OCTA, FFA, or ICGA.
- Your complete medical records and eye scan images must be available from before treatment, at 3 months, and at 1 year after starting anti-VEGF therapy.
- You cannot have other eye conditions that affect vision, like macular edema, glaucoma, or eye injury.
- You cannot have more than one type of macular lesion in the same eye.
- You must not have had any other eye treatments (like laser therapy or surgery) within 1 year before starting anti-VEGF therapy.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial uses artificial intelligence to track changes in the eyes of people with advanced age-related macular degeneration (AMD) that has caused a specific type of damage (atrophy) in the retina. The goal is to see if AI can help detect when the disease gets worse, so doctors can personalize monitoring for each patient.
This trial studies how genes affect response to anti-VEGF injections for a common form of age-related vision loss (wet AMD). It aims to tailor treatment to each patient.
This trial tests an investigational drug called SCT520FF for people with wet age-related macular degeneration (nAMD). It aims to find the safest dose and check if it can improve vision. You may be eligible if you have active new blood vessels in your eye from nAMD and have not had certain other eye problems.
This trial uses advanced imaging and artificial intelligence to predict how well patients with myopic macular neovascularization (a complication of severe nearsightedness) will respond to anti-VEGF injections over time. The goal is to identify who will benefit most from ongoing treatment.
This trial tests a new gene therapy called RRG001 for people with the 'wet' form of age-related macular degeneration. It aims to treat leaky blood vessels in the eye that can cause vision loss, possibly reducing the need for frequent eye injections.
This study uses artificial intelligence to track changes in the eyes of people with early or intermediate age-related macular degeneration (AMD). It aims to better understand how the disease progresses and may help doctors personalize care.
Hear when a new Age-related Macular Degeneration (ARMD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.